Skip to main content
. 2020 Mar 2;12(4):e11177. doi: 10.15252/emmm.201911177

Figure 3. Platinum treatment promotes ligand‐independent oncogenic EphA2 phosphorylation in vivo .

Figure 3

  • A
    Bioluminescence images visualize mock‐ and carboplatin‐treated OVCAR4 xenograft tumors (day 53; after 13‐d i.p. treatment). Color scale unit: p/sec/cm2/sr.
  • B, C
    Charts illustrate the tumor growth (B) and ascites volumes at the end of the follow‐up (C). Carboplatin treatment started on day 35. Bioluminescent unit: p/sec/cm2/sr. N = 5 mice/group.
  • D, E
    Representative micrographs of hematoxylin–eosin staining (D) and EphA2‐pS897 immunofluorescence (E) in the xenografts tumors. Scale bars: 100 μm (D), 10 μm (E).
  • F, G
    Quantitative assessment of tumor EphA2 (F) and EphA2‐pS897 (G). N = 5 mice/group.
  • H, I
    Confocal micrographs of tumor EphA2‐pS897 (red) and cleaved caspase‐3 (H; clCasp3, green) and corresponding clCasp3 quantification (I). Scale bars: 20 μm. N = 5 mice/group.
Data information: In (B and C; F and G; and I), data are presented as mean (SD). *P < 0.05, **P < 0.01. Exact P‐values are provided in Appendix Table S10, Mann–Whitney U‐test.Source data are available online for this figure.